Exact Sciences reported preliminary 2024 revenue of $2.76 billion (10% YoY growth), driven by strong performance in Screening ($2.1B, +13%) and Precision Oncology ($655M, +4%). The company plans to launch three cancer diagnostics in 2025: Cologuard Plus, an advanced colorectal cancer screening test; Oncodetect, a molecular residual disease test; and Cancerguard, a multi-cancer early detection blood test. With over 18 million patients screened by Cologuard since launch, the FDA-approved Cologuard Plus aims to further improve outcomes with reduced false positives. Exact Sciences’ precision oncology portfolio, including Oncotype DX and OncoExTra, continues to drive innovation in personalized cancer care, positioning the company for sustained growth and impact in cancer prevention, detection, and treatment.
Keep Reading
Add A Comment